(Q38904898)

7 September 2017

title

Novel vaccination approach for dengue infection based on recombinant immune complex universal platform (English)

1 reference

7 September 2017

0 references

Hugh S Mason

1 reference

7 September 2017

Mi-Young Kim

1 reference

7 September 2017

Rajko Reljic

1 reference

7 September 2017

Jacquelyn Kilbourne

1 reference

7 September 2017

Ivonne Ceballos-Olvera

1 reference

7 September 2017

Moon-Sik Yang

1 reference

7 September 2017

Jorge Reyes-del Valle

1 reference

7 September 2017

language of work or name

English

0 references

publication date

26 February 2015

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

1 reference

7 September 2017

page(s)

1830-1838

1 reference

A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

7 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Challenges in reducing dengue burden; diagnostics, control measures and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Dengue vaccines: progress and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Development of dengue DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Immune response to dengue virus and prospects for a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Dengue infection in children in Ratchaburi, Thailand: a cohort study. II. Clinical manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Identifying protective dengue vaccines: guide to mastering an empirical process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Geminivirus vectors for high-level expression of foreign proteins in plant cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

Geminivirus replication: genetic and biochemical characterization of Rep protein function, a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.02.036

10.1016/J.VACCINE.2015.02.036

7 January 2021

Identifiers

DOI

1 reference

7 September 2017

1 reference